Answers are grounded in this paper and cite their sources.
= 0.38). The present review aimed at describing the beneficial effect of PCSK9 inhibitors therapy early after ACS in reducing LDL circulating levels (LDL-C) and the risk of major adverse cardiovascular events, which was very high in the first year and persists higher later after the acute event.
No takes yet. Share an insight, caveat, or question.
Iannuzzo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: